Polycomb proteins in hematologic malignancies
Abstract
The Polycomb group (PcG) of proteins is a major mechanism of epigenetic regulation that has been broadly linked to cancer. This system can repress gene expression by chromatin modification and is essential for establishing cell identity. PcG proteins are important for stem cell function and differentiation and have a profound impact during hematopoiesis. In recent years, several published studies have deepened our knowledge of the biology of the PcG in health and disease. In this article, we review the current understanding of the mechanisms of PcG-mediated repression and their relation to DNA methylation, and we discuss the role of the PcG system in hematopoiesis and hematologic malignancies. We suggest that alteration of different PcG members is a frequent event in leukemia and lymphomas that confers the stem cell properties on tumor cells. Thus, drugs targeting Polycomb complexes could be useful for treating patients with these diseases.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
PRC2 is broadly linked to hematologic malignancies.
“Polycomb repressive complex 2 (PRC2) is one of the two major classes of polycomb proteins, which have been broadly linked to hematologic malignancies [147–149].”
From Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies (2020) · cites this paper as [147]
The citation lists haven’t been fetched yet
References 180 · Cited by 65
- Authors
- Martin-Perez, D., Piris, M. A., & Sanchez-Beato, M.
- Affiliations
- Lymphoma Group, Molecular Pathology Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain
- Spanish National Cancer Research Centre (ES)
- ORCID
- Piris, Miguel A.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2010-12-16
- Volume
- 116
- Issue
- 25
- Pages
- 5465-5475
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2029634407
- Cited by
- 65
- References
- 180
- Citations by year
- 2024: 1 · 2023: 2 · 2022: 1 · 2021: 4 · 2020: 1 · 2019: 2 · 2018: 2 · 2017: 8 · 2016: 5 · 2015: 3 · 2014: 9 · 2013: 6 · 2012: 14
- FWCI
- 0.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- Polycomb group proteins, hematologic malignancies, epigenetic regulation, gene silencing, chromatin modification, DNA methylation, hematopoiesis, leukemia, lymphoma, cancer stem cells
- MeSH terms
- Humans, Repressor Proteins, DNA Methylation, Hematologic Neoplasms, Epigenesis, Genetic, Polycomb-Group Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
